Hepatitis Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Hepatitis B Virus Therapy
Study data from Goteborg University update understanding of hepatitis B virus therapy
August 6th, 2007
New investigation results, "Mutation analysis of lamivudine resistant hepatitis B virus strains by TaqMan PCR," are detailed in a study published in Journal of Virological Methods. According to a study from Goteborg, Sweden, "Hepatitis B virus infected patients on long-term lamivudine treatment are exposed to a 15-32% risk compounded annually of developing resistance mutations. Such resistance results in a progression of the liver damage caused by chronic hepatitis B, and may also impair the effect of other antivirals through cross-resistance." "At present lamivudine is used frequently as monotherapy because of its relatively low price and negligible side...
Source: Hepatitis Weekly (2007-08-06)
|
